Accelerating the scale-up of adeno-associated virus (AAV) manufacture is highly desirable to meet the increased demand for gene therapies. However, the development of bioprocesses for AAV gene therapies remains time-consuming and challenging. Alongside this fast-moving clinical development, tools and technology providers are working hard to optimize technology to better serve these new modalities. Evaluation and implementation of advanced or novel technologies is therefore an ongoing process across the industry.

At Rentschler Biopharma, our platform approach encompasses bioprocess designs that address timeline challenges while maintaining desired product quality and safety profile. The novel tools and approaches that we have introduced, have the potential to streamline AAV product and bioprocess development. Here we discuss how the combination of platform framework and introduction of novel tools, contributed to accelerated development timelines. Furthermore, we share how this critically depends on improved analytical methods and the adaptation of new technologies.